Dr. Moul Discusses Immunotherapy in Prostate Cancer

September 2, 2015
Judd W. Moul, MD

Judd W. Moul, MD, urologic oncologist, Duke Medicine, discusses the impact of immunotherapy in prostate cancer.

Urologists are more aware of immunotherapy than most cancer specialists, says Moul. He and his colleagues have been working with Bacillus Calmette-Guérin (BCG) in bladder cancer for many years, as well as interleukin 2 in kidney cancer.

Sipuleucel-T (Provenge), commercialized by Dendreon, has also made quite a difference in prostate cancer, adds Moul. Unfortunately, this drug has never become widespread because of its perceived complexity of administration, as well as cost.

Judd W. Moul, MD, urologic oncologist, Duke Medicine, discusses the impact of immunotherapy in prostate cancer.